Key facts
- Notable investors include Redhill Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Inflamax Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Inflamax Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inflamax Pharmaceutical
Developer of innovative drugs designed for the field of immune inflammation. The company's drugs are mostly in the clinical stages and focus on treating immune inflammation and other diseases such as cancer, pain, neurological diseases and osteoarthritis by targeting key mechanisms and pathways in the tissue microenvironment, enabling doctors to correct the immune inflammatory response in an overreactive or underactive immune or inflammatory response pathology.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2022
- Website
- wo.cn/
- Ownership
- Privately Held (backing)
Inflamax Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inflamax Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inflamax Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.